IPO Year: 2024
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/2/2025 | $90.00 | Buy | H.C. Wainwright |
4/21/2025 | $60.00 | Buy | BTIG Research |
2/25/2025 | $50.00 → $55.00 | Overweight → Neutral | Analyst |
2/12/2025 | Outperform → Mkt Perform | William Blair | |
2/5/2025 | $58.00 → $74.00 | Buy | TD Cowen |
12/13/2024 | $60.00 | Outperform | Wolfe Research |
12/9/2024 | $74.00 | Buy | Guggenheim |
11/11/2024 | $45.00 → $65.00 | Buy → Hold | Stifel |
10/2/2024 | $45.00 → $60.00 | Buy → Neutral | BofA Securities |
8/12/2024 | $40.00 | Neutral | Piper Sandler |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Tempus AI, Inc. (0001717115) (Reporting)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4/A - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright initiated coverage of Tempus AI with a rating of Buy and set a new price target of $90.00
BTIG Research initiated coverage of Tempus AI with a rating of Buy and set a new price target of $60.00
Analyst downgraded Tempus AI from Overweight to Neutral and set a new price target of $55.00 from $50.00 previously
William Blair downgraded Tempus AI from Outperform to Mkt Perform
TD Cowen resumed coverage of Tempus AI with a rating of Buy and set a new price target of $74.00 from $58.00 previously
Wolfe Research initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $60.00
Guggenheim initiated coverage of Tempus AI with a rating of Buy and set a new price target of $74.00
Stifel downgraded Tempus AI from Buy to Hold and set a new price target of $65.00 from $45.00 previously
BofA Securities downgraded Tempus AI from Buy to Neutral and set a new price target of $60.00 from $45.00 previously
Piper Sandler initiated coverage of Tempus AI with a rating of Neutral and set a new price target of $40.00
144 - Tempus AI, Inc. (0001717115) (Subject)
SCHEDULE 13D/A - Tempus AI, Inc. (0001717115) (Filed by)
8-K - Tempus AI, Inc. (0001717115) (Filer)
424B7 - Tempus AI, Inc. (0001717115) (Filer)
144 - Tempus AI, Inc. (0001717115) (Subject)
144 - Tempus AI, Inc. (0001717115) (Subject)
144 - Tempus AI, Inc. (0001717115) (Subject)
DEF 14C - Tempus AI, Inc. (0001717115) (Filer)
144 - Tempus AI, Inc. (0001717115) (Subject)
PRE 14C - Tempus AI, Inc. (0001717115) (Filer)
Fastest customizable press release news feed in the world
The Ambry CARE Program® brings accurate, personalized breast cancer risk assessments directly into clinical workflows helping direct patients at high risk for breast cancer to seek additional screening Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ:TEM) and a pioneer in clinical genomic testing, today announced an enhancement to the Ambry CARE Program® (CARE), Ambry's digital platform that streamlines cancer risk assessment and genetic testing workflows. The update integrates breast density into the Tyrer-Cuzick (TC) breast cancer risk score within the electronic health record (EHR), providing clinicians with more precise and personalized risk estimates at the po
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its RNA-based Tempus xR IVD device. xR IVD will be offered as a life sciences tool to support drug development programs. RNA sequencing captures a large array of biological information and offers deeper insights into the mechanisms of diseases, including enhanced fusion detection. RNA analysis is increasingly an important tool in research and development because it can identify molecular pathways and networks that are directly involved in disease progression. "We
MarketNewsUpdates News Commentary NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Cell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been experiencing significant growth due to the rising awareness about the benefits of cell therapies. They help regenerate damaged tissues and organs. They have the potential to treat a range of conditions, such as cancer, autoimmune diseases, infectious diseases, urinary issues, spinal cord injuries, joint cartilage damage, immune system weakness, and neurological disorders. Cell therapies target only damaged tissues, reducing the chances of getting damage to other tissues. Numerous cell types are
Definitive agreement to accelerate adoption of Renalytix's FDA-approved, Medicare reimbursed kidneyintelX.dkd test to slow kidney disease progression and improve patient outcomes NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB:RNLXY), today announced an agreement with Tempus AI, Inc. (NASDAQ:TEM) to make kidneyintelX.dkd prognostic blood testing more widely available for eligible patients within its US network of healthcare institutions. Eligible patients have type 2 diabetes with chronic kidney disease, impacting nearly 15 million individuals in the US.
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel, an AI-powered cardiac imaging platform. This update allows the generation of T1 and T2 inline maps, further enhancing the device's capabilities for cardiac MR image analysis. Tempus Pixel provides advanced viewing and automated reporting of cardiac MR images, improving efficiency and accuracy in flow visualization, functional analysis, and tissue characterization. AI-enabled radiology, like Tempus Pixel, enhances medical imaging by rapidly analyzing scans,
Real-world evidence demonstrates PurIST's ability to guide first-line treatment decisions and improve outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the publication of a study in JCO Precision Oncology validating the clinical utility of the company's PurIST® algorithmic diagnostic. The study provides the largest real-world evidence to date supporting the integration of PurIST into routine clinical care for patients with advanced PDAC, with the aim of informing first-line chemotherapy selection and improving patient outcomes. Pancreatic
Tempus' generative AI-enabled clinical assistant is designed to support providers in unlocking new insights and efficiencies Northwestern Medicine and Tempus AI, Inc. (NASDAQ:TEM) today announced a notable expansion of their longstanding collaboration. Northwestern Medicine will be the first health system to integrate David, Tempus' generative-AI clinical co-pilot, within its electronic health record (EHR) platform for its clinical care team. The expanded collaboration marks a new chapter in the organizations' shared commitment to harnessing data and AI to advance patient care. Northwestern Medicine and Tempus clinical, operations, and technical teams are working together to customize t
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in Morgan Stanley's 23rd Annual Global Healthcare Conference. The conference will take place September 8-10 in New York City. Eric Lefkofsky, Founder and CEO of Tempus, and Jim Rogers, Chief Financial Officer, will participate in a fireside chat on September 8 from 1:05 to 1:40 p.m. EST. A live audio webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of mu
Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended June 30, 2025. Revenue increased 89.6% year-over-year to $314.6 million in the second quarter Genomics revenue increased 115.3% year-over-year to $241.8 million on accelerating year-over-year volume growth in Oncology (26%) and Hereditary (32%) testing Data and services revenue increased 35.7% year-over-year to $72.8 million, led by Insights (data licensing), which grew 40.7% year-over-year Quarterly gross profit was $195.0 million, a 158.3% year-over-year increase Issued $750 million of 0.75% conv
This live feed shows all institutional transactions in real time.
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13D - Tempus AI, Inc. (0001717115) (Filed by)
Live finance-specific insights
Paige's strong foundation in pathology and AI is rooted in its proprietary dataset of almost 7 million digitized pathology slides that are clinically annotated Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio. Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowin
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7005219 Domestic Dial-in Number: (800) 715-9871 International Dial-in Numbe
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4680302 Domestic Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 9601821 Domestic Dial-in Number: (888) 596-4144 International Dial-i
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7177136 Domestic Dial-in Number: (800) 715-9871 International Dial-in
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter on Tuesday, August 6, 2024. The company will hold the second quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 6326328 Domestic Dial-in Number: (800) 715-9871 International Dial-in